Watson Pharmaceuticals announced that the company recently received the “Drug Registration Certificate” for orlistat capsules approved and issued by the State Drug Administration. Both drugs are Class 4 and Class A non-prescription drugs, and the drug approval number is valid until October 12, 2031. This approval is conducive to enriching the company's metabolic disease product pipeline and providing a product foundation for expanding the out-of-hospital market. There is uncertainty about drug production and sales due to factors such as industry policies and market competition.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.